Wednesday, July 8, 2026
🇺🇸 FDA

pharma · No medical condition. · Breast cancer

George Institute for

The George Institute

George Institute for clinical programs — 187 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Sydney, NSW 2042, AU HQ
1999 Founded
841 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Sydney, NSW 2042, AU
Founded
1999
Employees
841
Programs
406
Drugs
522
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Clinical Programs

George Institute for projects

187 ClinicalTrials.gov programs sponsored by George Institute for.

George Institute for has 187 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

187 programs

Clinical programs

Page 2 of 4

  1. CSET 2025/4053

    The George Institute

    Breast cancer

    phase 2 small molecule active

    1 trial

  2. CSET N° 2017/2523

    The George Institute

    Pancreatic well differentiated neuroendocrine tumors (NET)

    phase 2 other active

    1 trial

  3. CSET N° 2020/3188

    The George Institute

    Patients with hormone-receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-negative) advanced breast cancer (ABC) who have already received standard therapy for HR+/HER2-negative ABC, including only one line of chemotherapy for advanced/metastatic disease.

    phase 2 other active

    1 trial

  4. CSET N°2016/2454

    The George Institute

    Metastatic squamous cell carcinoma of head and neck, lung, esophagus, cervix, vagina, vulva or anus to be treated with SBRT

    phase 2 small molecule active

    1 trial

  5. CSET N°2017/2536

    The George Institute

    Adjuvant therapy after salvage surgery of high risk recurrent head and neck squamous cell carcinoma (HNSCC)

    phase 2 small molecule active

    1 trial

  6. CSET N°2020/3138

    The George Institute

    Advanced hepatocellular carcinoma

    phase 2 other active

    1 trial

  7. CSET n° 2020/3210

    The George Institute

    Untreated small triple negative breast cancer

    phase 2 other active

    1 trial

  8. CYSTAGON 150 mg hard capsules

    The George Institute

    Infectious diseases of respiratory system (COVID-19)

    phase 2 small molecule active

    1 trial

  9. CYSTAGON 50 mg hard capsules

    The George Institute

    Pulmonary Tuberculosis

    phase 2 small molecule active

    1 trial

  10. Curosurf for Premature infants with Respiratory Distress Syndrome (RDS)

    The George Institute

    Premature infants with Respiratory Distress Syndrome (RDS)

    phase 2 small molecule active

    1 trial

  11. DASATINIB, Placebo

    The George Institute

    Asymptomatic patients with recent HIV-1 infection

    phase 2 small molecule active

    1 trial

  12. Doxycycline EG 200 mg Tabletten

    The George Institute

    Bacterial sexually transmittable diseases (chlamydia, gonorrhea, syphilis)

    phase 2 small molecule active

    1 trial

  13. EFAVIRENZ

    The George Institute

    Type C Niemann-Pick Disease

    phase 2 small molecule active

    1 trial

  14. EMBRACE

    The George Institute

    SEPSIS

    phase 2 small molecule active

    1 trial

  15. ENCORAFENIB , CETUXIMAB

    The George Institute

    Patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) who had received and responded to a BRAF inhibitor-based treatment.

    phase 2 small molecule active

    1 trial

  16. ENDORET-PRGF

    The George Institute

    glaucoma

    phase 2 small molecule active

    1 trial

  17. ENHANCE

    The George Institute

    Intermediate risk prostate cancer

    phase 2 small molecule active

    1 trial

  18. EPLERENONE

    The George Institute

    Heart failure with reduced ejection fraction in combination with severe chronic kidney disease

    phase 2 small molecule active

    1 trial

  19. ETNA

    The George Institute

    Relapsed/refractory neuroblastoma and other solid tumours

    phase 2 small molecule active

    1 trial

  20. FRACTION_2021

    The George Institute

    Primary and secondary Myelofibrosis

    phase 2 small molecule active

    1 trial

  21. FULVESTRANT for advanced breast cancer

    The George Institute

    advanced breast cancer

    phase 2 small molecule active

    1 trial

  22. FUTURE

    The George Institute

    Colorectal cancer

    phase 2 small molecule active

    1 trial

  23. Fludarabina Accord /ml concentrado para soluc...

    The George Institute

    Refractary or relapse non-Hodgkin T CD30+ lymphoma., Refractary or relapse Hodgkin T CD30+ lymphoma

    phase 2 small molecule active

    1 trial

  24. GEM-PLASMACAR

    The George Institute

    Plasma cell leukaemia

    phase 2 small molecule active

    1 trial

  25. Glofitamab for previously untreated aggressive B-cell lymphoma

    The George Institute

    previously untreated aggressive B-cell lymphoma

    phase 2 small molecule active

    1 trial

  26. Grafalon 20 mg/ml koncentrát pro infuzní roztok

    The George Institute

    Type 1 diabetes

    phase 2 small molecule active

    1 trial

  27. HIPER-RESET

    The George Institute

    chronic kidney disease, Hypersensitized patients

    phase 2 other active

    1 trial

  28. IB 2018-04

    The George Institute

    Adult patients with locally advanced/unresectable and/or metastatic soft-tissue leiomyosarcomas.

    phase 2 small molecule active

    1 trial

  29. IB 2019-01

    The George Institute

    Adult participants with metastatic (advanced) solid tumors.

    phase 2 small molecule active

    1 trial

  30. IB 2019-03

    The George Institute

    Adult participants with advanced unresectable or metastatic soft-tissue sarcoma.

    phase 2 small molecule active

    1 trial

  31. IB 2019-04

    The George Institute

    Adult participants with metastatic or unresectable locally advanced solid tumors.

    phase 2 small molecule active

    1 trial

  32. IB 2019-07

    The George Institute

    Patients with locally advanced or metastasic Non-Small Cell Lung Carcinoma.

    phase 2 small molecule active

    1 trial

  33. IB 2020-02

    The George Institute

    Advanced /metastatic sarcomas: undifferentiated pleomorphic sarcoma, osteosarcoma and Ewing sarcoma.

    phase 2 small molecule active

    1 trial

  34. IB 2020-05

    The George Institute

    Adult patients with locally advanced/unresectable and/or metastatic soft-tissue sarcomas.

    phase 2 small molecule active

    1 trial

  35. IB 2021-01

    The George Institute

    Adult patients with treatment-naïve surgically non-metastatic and resectable primary retroperitoneal, limbs and trunk wall undifferentiated pleomorphic sarcomas.

    phase 2 small molecule active

    1 trial

  36. IB 2021-03

    The George Institute

    Adult patients with intermediate unfavorable risk prostate cancer as per NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines Prostate Cancer. Version 2.2021)

    phase 2 small molecule active

    1 trial

  37. IB 2023-02

    The George Institute

    Adult patients with locally advanced/metastatic solid tumors

    phase 2 small molecule active

    1 trial

  38. IC 2009-04

    The George Institute

    Retinoblastoma

    phase 2 small molecule active

    1 trial

  39. IC 2011-05

    The George Institute

    Retinoblastoma

    phase 2 small molecule active

    1 trial

  40. IC 2019-02

    The George Institute

    Primary Central Nervous System Lymphoma (PCNSL)

    phase 2 other active

    1 trial

  41. IC 2019-05

    The George Institute

    Ocular conservative treatment for retinoblastoma

    phase 2 small molecule active

    1 trial

  42. IC 2020-06

    The George Institute

    Metastatic uveal melanoma

    phase 2 other active

    1 trial

  43. IC 2022-07

    The George Institute

    Breast cancer

    phase 2 small molecule active

    1 trial

  44. IC 2024-01

    The George Institute

    HER3-mutant and HER2-not amplified metastatic breast cancer

    phase 2 small molecule active

    1 trial

  45. ICI21/00031

    The George Institute

    Actinic keratoses

    phase 2 small molecule active

    1 trial

  46. ICONICplus

    The George Institute

    Alcohol dependence

    phase 2 small molecule active

    1 trial

  47. IFG-05-2019

    The George Institute

    patients with unresectable or metastatic HER2 negative breast cancer and a deleterious germline mutation in BRCA 1/2, ATM, BARD1, CHEK2, FANCC, PALB2, RAD51C, RAD51D, SLX4, XRCC2 or a homologous recombination deficiency

    phase 2 small molecule active

    1 trial

  48. IIBSP-HEA-2022-145

    The George Institute

    cognitive impairment

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does George Institute for have?

187 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.